Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Special Issue in Honour of the Editor-in-Chief Prof. Dr. Ing. Friedrich Jung on his 70th Birthday
Article type: Research Article
Authors: Anadol, Remzi | Dimitriadis, Zisis | Polimeni, Alberto | Wendling, Franziska | Gönner, Svenja | Ullrich, Helen | Lorenz, Liv | Weissner, Melissa | Munzel, Thomas | Gori, Tommaso; *
Affiliations: Kardiologie I, Universitätsmedizin Mainz und DZHK Standort Rhein-Main, Mainz, Germany
Correspondence: [*] Corresponding author: Tommaso Gori, Zentrum für Kardiologie, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany. Tel.: +49 6131 17 2829; Fax: +49 6131 17 6428; E-mail: tommaso.gori@unimedizin-mainz.de.
Note: [1] The manuscript is dedicated to Prof. F. Jung on the occasion of his 70th birthday.
Abstract: AIM:To investigate three-year outcomes of patients presenting with nonSTelevation acute coronary syndrome (NSTE-ACS) treated with bioresorbable everolimus-eluting vascular scaffolds (BRS). METHODS AND RESULTS:The study included a total of 488 consecutive patients, enrolled between May 2012 and December 2013 (median age 65 [56–74], 392 men. 269 patients presented with either NSTEMI or unstable angina at the time of enrolling, 219 patients with stable or silent angina. The primary device-oriented endpoint (Target Lesion Failure, TLF) was defined as a combination of cardiovascular death, target vessel myocardial infarction or clinically driven target lesion revascularization.Among the cardiac risk factors, NSTE-ACS patients were more frequently smokers (P = 0.028), had less frequently dyslipidemia (P = 0.003) and a history of prior PCI (P < 0.01).The median follow-up was 1070[763–1197] days. The three-years incidence of TLF was slightly higher but did not differ significantly between groups (NSTE-ACS: 16.3% vs. 15.9%, p = 0.163). Accordingly, there was no difference in any of the other endpoints. CONCLUSION:Treatment of NSTE-ACS with BRS appears to be safe and effective. In this group, risk factors for events during follow up did not differ as compared to the general population.
Keywords: Bioresorbable scaffolds, acute coronary syndromes, coronary
DOI: 10.3233/CH-189101
Journal: Clinical Hemorheology and Microcirculation, vol. 69, no. 1-2, pp. 3-8, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl